Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

VitaNova Life Sciences (YJGJ) EBT Margin (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed EBT Margin for 7 consecutive years, with 23.25% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 244.0% year-over-year to 23.25%, compared with a TTM value of 44.97% through Oct 2025, up 1881.0%, and an annual FY2025 reading of 45.24%, up 919.0% over the prior year.
  • EBT Margin was 23.25% for Q4 2025 at VitaNova Life Sciences, up from 31.22% in the prior quarter.
  • Across five years, EBT Margin topped out at 55.33% in Q2 2025 and bottomed at 245.77% in Q1 2023.
  • Average EBT Margin over 5 years is 14.75%, with a median of 22.79% recorded in 2024.
  • The sharpest move saw EBT Margin tumbled -27549bps in 2023, then soared 26856bps in 2024.
  • Year by year, EBT Margin stood at 33.35% in 2021, then decreased by -22bps to 26.01% in 2022, then plummeted by -662bps to 146.17% in 2023, then skyrocketed by 114bps to 20.8% in 2024, then increased by 12bps to 23.25% in 2025.
  • Business Quant data shows EBT Margin for YJGJ at 23.25% in Q4 2025, 31.22% in Q3 2025, and 55.33% in Q2 2025.